All In Biotech

Drug Trial Radar · NCT06905314

A Single Ascending Dose of HRS-4029 in Healthy Subjects

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HRS-4029 Following a Single Dose in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Apr 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

55

Planned (sponsor's estimate)

Start

Apr 2025

Primary completion

Oct 2025

Study completion Dec 2025

Sponsor

Sponsor type
Industry
First posted
Apr 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the safety, tolerability and pharmacokinetics of HRS-4029 following a single intravenous dose administration in healthy subjects.

Conditions

  • Acute Ischemic Stroke

Interventions

  • HRS-4029Drug

    HRS-4029

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence and severity of adverse eventsTime frame: From ICF signing date to Day15

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • China-Japan Friendship Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.